The small molecule WNT/β-catenin inhibitor CWP232291 blocks the growth of castration-resistant prostate cancer by activating the endoplasmic reticulum stress pathway

Abstract

Background Androgen receptor (AR)-targeted treatments improve the survival of castration-resistant prostate cancer (CRPC) patients; however, secondary resistance to these agents ultimately occurs in virtually all patients. Therefore, alternative therapeutic targets are urgently needed. Since growing evidence demonstrates that WNT/β-catenin signaling plays an important role in CRPC, the antitumor activity and mechanism of action of CWP232291, a small molecule β-catenin inhibitor, were investigated in prostate cancer. Methods We assessed the antitumor activity of CWP232291 in prostate cancer cell lines and primary cells derived from CRPC patients. The effect of CWP232291 on apoptotic cell death, endoplasmic reticulum (ER) stress, cell viability, and WNT/β-catenin signaling was evaluated by flow cytometry, western blotting, luciferase reporter assay, and fluorescence microscopy. Antitumor efficacy was assessed in two CRPC xenograft mouse models. Results CWP232291 induced ER stress, resulting in upregulation of the proapoptotic protein CHOP and activation of caspase-3-dependent apoptosis. In addition, CWP232291 suppressed the expression of β-catenin by affecting WNT-dependent transcriptional activity, and downregulated AR and its splice variants in prostate cancer cells. Antitumor activity was observed in prostate cancer cells in vitro and ex vivo, and antitumor efficacy was observed in vivo. Conclusions Beyond providing preclinical evidence of therapeutic efficacy for the novel small molecule β-catenin inhibitor CWP232291 in CRPC, our results show that inducing ER stress and targeting WNT/β-catenin signaling may be a novel strategy against CRPC. Electronic supplementary material The online version of this article (10.1186/s13046-019-1342-5) contains supplementary material, which is available to authorized users.

Isoalantolactone Increases the Sensitivity of Prostate Cancer Cells to Cisplatin Treatment by Inducing Oxidative Stress

“…ER stress occurs when there is accumulation of misfolded proteins in the ER lumen. It has been reported that isobavachalcone, δ-tocotrienol, and CWP232291 could induce ER stress-mediated apoptosis in prostate cancer cells (Li et al, 2018;Fontana et al, 2019;Pak et al, 2019). In accordance with these studies, we found that IATL and cisplatin combination significantly increased the levels of ER stress-related proteins, such as p-eIF2α, ATF4, and CHOP in DU145 and PC-3 cells.…”

Metformin Reduces NGF-Induced Tumour Promoter Effects in Epithelial Ovarian Cancer Cells

“…Binding of β-catenin to the T-cell factor/lymphoid enhancer-binding factor (TCF/Lef) family of transcription factors promotes transcription of many oncogenes following activation of the canonical Wnt signalling pathway [ 27 , 28 , 29 ]. For instance, the β-catenin/TCF-Lef complex increases the expression of proteins associated with epithelial-mesenchymal transition (EMT) [ 30 , 31 ], as well as those relating to cell survival and cell proliferation, including survivin and c-MYC [ 32 , 33 ]. Both proteins in turn promote β-catenin/TCF-Lef activity, in an amplification loop that could be involved in tumour growth and EOC progression.…”

<p>The Role of β-Arrestin1 in Esophageal Squamous Cell Carcinoma</p>

“…PI3K/Akt and Wnt/β-catenin signaling pathway inhibitors, as newly emerged targeted drugs in recent years, provide a new treatment scheme for various common tumors. 21,22 Moreover, researches indicated that β-arrestin1 could affect Aktdependent pathway and GSK-3β/β-catenin signaling. 17,18 We evaluated that overexpression of β-arrestin1 markedly promoted the activation of AKT/GSK3β/β-catenin pathway, while knockdown of β-arrestin1 reversed this effect.…”